Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab

NRG Oncology/GOG study

Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, Harry J. Long, Andrés Poveda, Lisa M. Landrum, Mario M. Leitao, Jubilee Brown, Thomas J A Reid, Helen Michael, David H. Moore

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval

Original languageEnglish (US)
Pages (from-to)5480-5487
Number of pages8
JournalClinical Cancer Research
Volume21
Issue number24
DOIs
StatePublished - Dec 15 2015

Fingerprint

Uterine Cervical Neoplasms
Cisplatin
Research Design
Drug Therapy
Survival
Bevacizumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab : NRG Oncology/GOG study. / Tewari, Krishnansu S.; Sill, Michael W.; Monk, Bradley J.; Penson, Richard T.; Long, Harry J.; Poveda, Andrés; Landrum, Lisa M.; Leitao, Mario M.; Brown, Jubilee; Reid, Thomas J A; Michael, Helen; Moore, David H.

In: Clinical Cancer Research, Vol. 21, No. 24, 15.12.2015, p. 5480-5487.

Research output: Contribution to journalArticle

Tewari, KS, Sill, MW, Monk, BJ, Penson, RT, Long, HJ, Poveda, A, Landrum, LM, Leitao, MM, Brown, J, Reid, TJA, Michael, H & Moore, DH 2015, 'Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG study', Clinical Cancer Research, vol. 21, no. 24, pp. 5480-5487. https://doi.org/10.1158/1078-0432.CCR-15-1346
Tewari, Krishnansu S. ; Sill, Michael W. ; Monk, Bradley J. ; Penson, Richard T. ; Long, Harry J. ; Poveda, Andrés ; Landrum, Lisa M. ; Leitao, Mario M. ; Brown, Jubilee ; Reid, Thomas J A ; Michael, Helen ; Moore, David H. / Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab : NRG Oncology/GOG study. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 24. pp. 5480-5487.
@article{b5b83cec076d45da9af2bb501c79afbf,
title = "Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG study",
abstract = "Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval",
author = "Tewari, {Krishnansu S.} and Sill, {Michael W.} and Monk, {Bradley J.} and Penson, {Richard T.} and Long, {Harry J.} and Andr{\'e}s Poveda and Landrum, {Lisa M.} and Leitao, {Mario M.} and Jubilee Brown and Reid, {Thomas J A} and Helen Michael and Moore, {David H.}",
year = "2015",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-15-1346",
language = "English (US)",
volume = "21",
pages = "5480--5487",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab

T2 - NRG Oncology/GOG study

AU - Tewari, Krishnansu S.

AU - Sill, Michael W.

AU - Monk, Bradley J.

AU - Penson, Richard T.

AU - Long, Harry J.

AU - Poveda, Andrés

AU - Landrum, Lisa M.

AU - Leitao, Mario M.

AU - Brown, Jubilee

AU - Reid, Thomas J A

AU - Michael, Helen

AU - Moore, David H.

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval

AB - Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval

UR - http://www.scopus.com/inward/record.url?scp=84954088146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954088146&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1346

DO - 10.1158/1078-0432.CCR-15-1346

M3 - Article

VL - 21

SP - 5480

EP - 5487

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -